Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$104.96 USD

104.96
199,146

-1.82 (-1.70%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $105.03 +0.07 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.

Zacks Equity Research

Why Addus HomeCare (ADUS) Could Beat Earnings Estimates Again

by Zacks Equity Research

Addus HomeCare (ADUS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

What's in Store for Thermo Fisher (TMO) in Q2 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.

Zacks Equity Research

UnitedHealth Group (UNH) Q2 Earnings Beat, Boosts '23 EPS View

by Zacks Equity Research

UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.

Debanjana Dey headshot

4 Stocks to Hold in a Challenging Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.

Zacks Equity Research

Bruker (BRKR) Launches ENRICH-iST Kits and Novel Workflow

by Zacks Equity Research

Bruker's (BRKR) ENRICH-iST kit is ready to use right out of the box. The workflow is simple to understand and fully automatable.

Zacks Equity Research

Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod

by Zacks Equity Research

Teleflex's (TFX) Wattson Temporary Pacing Guidewire offers dual functionality, allowing both valve delivery and ventricular bipolar pacing during TAVR or BAV treatments.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Neogen (NEOG) Launches Genomic Test for Beef-on-Dairy Calves

by Zacks Equity Research

Neogen's (NEOG) new Igenity BeefXDairy test is an additional tool, enabling producers to gather crucial data they need to advance and grow their operations effectively and sustainably.

Zacks Equity Research

Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer

by Zacks Equity Research

Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.

Zacks Equity Research

Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?

by Zacks Equity Research

The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.

Zacks Equity Research

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) owing to expanding work-flow options of its leading iTero scanners.

Zacks Equity Research

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Illumina's (ILMN) New AI Tool to Predict Genomics Disease

by Zacks Equity Research

Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Zacks Equity Research

Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves

by Zacks Equity Research

Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.

Zacks Equity Research

Charles River (CRL) to Build RightSource Lab With New Pact

by Zacks Equity Research

Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.

Zacks Equity Research

Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses

by Zacks Equity Research

Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.

Zacks Equity Research

Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.

Zacks Equity Research

Wall Street Analysts Predict a 28.56% Upside in Addus HomeCare (ADUS): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Addus HomeCare (ADUS) points to a 28.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Medtronic (MDT) to Expand Diabetes Care With New Buyout

by Zacks Equity Research

Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.

Zacks Equity Research

Thermo Fisher (TMO) Expands Manufacturing Facility in APAC

by Zacks Equity Research

Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.

Zacks Equity Research

Here's Why Investors Should Add Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.